Group items tagged

This Funding Opportunity Announcement (FOA) seeks grant applications to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.

This FOA seeks applications on research to develop techniques, tools, and methodologies that improve detection and assessment of CO2 stored in the target reservoir. Research products developed under this FOA are expected to include monitoring tools and techniques, as well as validation of models and modeling techniques. Successful technologies developed under this FOA will decrease the operator's financial burden associated with long-term monitoring by providing them the capability to assess the position of the CO2 plume in the target reservoir with greater certainty throughout the life cycle of the project (i.e., active- and post-injection).

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of CUDs or their consequences such as withdrawal, craving, or cannabis use relapse. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of CUDs. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

This Broad Agency Announcement (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the development, testing, and scaling of innovative approaches that address critical global health challenges. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, in response to a Global Health Challenge Addenda issued under this BAA, as described below, to provide innovative interventions and technologies that further the U.S. Government's commitment to prevent and manage critical global health challenges.

This Broad Agency Announcement (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the development, testing, and scaling of innovative approaches that address critical global health challenges. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, in response to a Global Health Challenge Addenda issued under this BAA, as described below, to provide innovative interventions and technologies that further the U.S. Government's commitment to prevent and manage critical global health challenges.

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. In support of these aims, this FOA seeks applications for a community-driven project to develop computational and informatics tools for the manipulation, analysis, interpretation, and integration of glycoscience data. The product of this research will be accessible resources for analysis of carbohydrate and glycoconjugate structural, analytical, and interaction data, and integration of that information within the context of comparable gene, protein, and lipid data and databases.

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. In support of these aims, this FOA seeks applications for a community-driven project to develop computational and informatics tools for the manipulation, analysis, interpretation, and integration of glycoscience data. The product of this research will be accessible resources for analysis of carbohydrate and glycoconjugate structural, analytical, and interaction data, and integration of that information within the context of comparable gene, protein, and lipid data and databases.  

This FOA solicits development of innovative adaptations of existing technologies to enable their use for readily identifying, manipulating, or analyzing glycans and their biological binding partners. This may encompass the adaptation of commonly used laboratory-based or computational tools to enable their facile application to glycoscience for the first time, as well as the adaptation of tools presently used by specialists in glycoscience to make them significantly more straightforward and accessible for non-specialists. It is possible that a project might simplify a current specialized approach by migrating it to a more commonly used platform, developing automation for data acquisition and interpretation, or redesigning the present tool to make it easier to use. This announcement differs from the related FOA RFA- RM-16-022 which solicits new or more effective tools or technologies, thus representing an expansion of existing technologies.

This FOA solicits development of innovative adaptations of existing technologies to enable their use for readily identifying, manipulating, or analyzing glycans and their biological binding partners. This may encompass the adaptation of commonly used laboratory-based or computational tools to enable their facile application to glycoscience for the first time, as well as the adaptation of tools presently used by specialists in glycoscience to make them significantly more straightforward and accessible for non-specialists. It is possible that a project might simplify a current specialized approach by migrating it to a more commonly used platform, developing automation for data acquisition and interpretation, or redesigning the present tool to make it easier to use. This announcement differs from the related FOA RFA- RM-16-022 which solicits new or more effective tools or technologies, thus representing an expansion of existing technologies.

The Chemical Measurement and Imaging Program supports research focusing on chemically-relevant measurement science and chemical imaging, targeting both improved understanding of new and existing methods and development of innovative approaches and instruments.  Research areas include but are not limited to sampling and separation science; electroanalytical chemistry; spectrometry; and frequency- and time-domain spectroscopy.  Development of new chemical imaging and measurement tools probing chemical properties and processes are supported.  Innovations enabling the monitoring and imaging of chemical and electronic processes across a wide range of time and length scales are also relevant.  New approaches to data analysis and interpretation (including chemometrics) are encouraged.  Proposals addressing established techniques must seek improved understanding and/or innovative approaches to substantially broaden applicability.  Sensor-related proposals should address new approaches to chemical sensing, with prospects for broad utility and significant enhancement of current capabilities.

The Chemical Measurement and Imaging Program supports research focusing on chemically-relevant measurement science and chemical imaging, targeting both improved understanding of new and existing methods and development of innovative approaches and instruments.  Research areas include but are not limited to sampling and separation science; electroanalytical chemistry; spectrometry; and frequency- and time-domain spectroscopy.  Development of new chemical imaging and measurement tools probing chemical properties and processes are supported.  Innovations enabling the monitoring and imaging of chemical and electronic processes across a wide range of time and length scales are also relevant.  New approaches to data analysis and interpretation (including chemometrics) are encouraged.  Proposals addressing established techniques must seek improved understanding and/or innovative approaches to substantially broaden applicability.  Sensor-related proposals should address new approaches to chemical sensing, with prospects for broad utility and significant enhancement of current capabilities.

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

This funding opportunity announcement (FOA) encourages applications from institutions/organizations that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development. Potential applicants may also be interested in the FOA Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01).

The Chemical Synthesis program focuses on the development of new, efficient synthetic methodologies and on the synthesis of complex and/or challenging molecules.  Typical synthetic targets involve novel structures, structures displaying unique properties, or structures providing pathways to discover and elucidate new phenomena.  Examples of supported research areas include the development of innovative reagents, catalysts for synthetic transformations, discovery of new synthetic methods, target-oriented synthesis, green synthesis, and synthesis of novel organic, organometallic, and inorganic structures.  Research in this program will generate fundamental knowledge of chemical synthesis that enables the development of new avenues of basic chemical research and transformative technologies. 

Recognizing disciplinary differences and priorities, NSF's investment in research and development in undergraduate STEM education encompasses a range of approaches. These approaches include: experiential learning, assessment/metrics of learning and practice, scholarships, foundational education research, professional development/institutional change, formal and informal learning environments, and undergraduate disciplinary research. Both individually and integrated in a range of combinations, these approaches can lead to outcomes including: developing the STEM and STEM-related workforce, advancing science, broadening participation in STEM, educating a STEM-literate populace, improving K-12 STEM education, encouraging life-long learning, and building capacity in higher education.

The Chemical Synthesis program focuses on the development of new, efficient synthetic methodologies and on the synthesis of complex molecules and molecular ensembles. Typical synthetic targets involve novel structures, structures displaying unique properties, or structures providing pathways to discover and elucidate new phenomena. Examples of supported research areas include the development of innovative reagents, catalysts for synthetic transformations, discovery of new synthetic methods, target-oriented synthesis, green synthesis, and synthesis of novel organic, organometallic, and inorganic structures. Research in this program will generate fundamental knowledge of chemical synthesis that enables the development of new avenues of basic chemical research and transformative technologies. The Chemical Synthesis program does not support projects whose main objective is on the property of the systems even though it may involve a large synthetic component.

he purpose of this program is to investigate and evaluate advanced fuels and fuel technologies, fuel system component development, advanced combustor and augmentor designs, advanced fuel properties measurements, fuel system component development and safety and combustion emissions along with their integration into advanced aerospace applications and advanced technologies to prevent and mitigate fuel biodeterioration. Research will be performed to characterize and develop advanced fuels- and combustion-related technologies for use at all operating conditions in current and advanced weapons systems. 

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

A global automobile parts manufacturer, a client of NineSigma, believes credible air cleaning technology is key to comfortable automobile experience; particularly deodorization and sterilization technology will become increasingly important. The Client has promoted research and development on their own, however they now face a challenge to find a suitable solution to ensure both deodorization/sterilization and safety in a short time. Given that technological development of such air cleaning is done globally, the Client decided to find a partner to further accelerate the development speed, which lead to this offering.

CHE supports a large and vibrant research community engaged in fundamental discovery, invention, and innovation in the chemical sciences. The projects supported by CHE explore the frontiers of chemical science, develop the foundations for future technologies and industries that meet changing societal needs, and prepare the next generation of chemical researchers. Some of the areas supported by CHE include: designing, synthesizing and characterizing new molecules, catalysts, surfaces, and nanostructures - especially those with a focus on sustainability; increasing our fundamental understanding of chemical species and their chemical transformations, kinetics, and thermodynamics; developing new tools and novel instrumentation for chemical discovery, including those in sensing, communication, and data discovery science where increasing volumes and varieties of data are harnessed to advance innovation; determining structure-function relationships in biological systems and contributing to our understanding of the fundamental rules of life; observing, manipulating, and controlling the behavior of matter and energy in nanometer dimensions such as the quantum regime; understanding chemical processes in the environment; and solving complex chemical problems by the development of new theories, computations, models, and tools, including the synergistic combination of multiple types of instruments.

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative multipurpose prevention technologies (MPT) with rheological/biophysical properties and product user perceptions compatible with current long-acting reversible contraceptive (LARC) strategies (look, feel, effectiveness, safety and duration of action) for the dual purpose of preventing pregnancy and HIV infection in women. MPTs proposed for development must be dual indication and prevent pregnancy and HIV infection and have drug delivery systems (DDS) capable with sustained/extended release of both drugs. MPTs proposed for development must use a licensed contraceptive. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires submission of a pre-IND application to the FDA.

This Cooperative Agreement is a 5-year project for development and implementation of a Native Water Leasing Pilot Program for the Middle Rio Grande (MRG) to be developed and implemented jointly by the National Fish and Wildlife Foundation (NFWF) and the Bureau of Reclamation (Reclamation) in coordination with the Middle Rio Grande Conservancy District (MRGCD). Water acquired under the Program will be used to support implementation of the December 2016 Final Biological Opinion for Bureau of Reclamation, Bureau of Indian Affairs, and Non-Federal Water Management and Maintenance Activities on the Middle Rio Grande, New Mexico (2016 BiOp). The primary focus of the Cooperative Agreement is to develop and implement the cooperative pilot Program with MRGCD and willing sellers over a 5-year implementation period to acquire water for environmental use in the MRG. Through pilot implementation, the Program will set the stage for expanded native water leasing and other voluntary measures at scale as win-win solutions for the river, local communities, agricultural producers, and MRGCD over the long term. Further, it provides a key component of a large-scale long-term opportunity to combine instream water leasing with the restoration of riparian and upper watershed habitats along with other initiatives to advance landscape-scale restoration in the MRG. Areas where collaboration with other agencies and partner organizations will broaden the scope of the effort, leverage additional funding, and increase the prospects for long-term success will be identified throughout the effort.

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.